While LDL cholesterol lowering has, understandably, remained the mainstay in the primary and secondary prevention of ASCVD, a Disclosure: MDS sits on the scientific advisory boards of Amgen and Regeneron. AA has no conflicts of interest to declare.
There are several key differences between the European and American guidelines, the first of which lies in the definition and treatment thresholds for very high risk patients. Table 1 [16] [17] [18] [19] Adenosine triphosphate citrate lyase inhibitor 
